No	REC Ref	IRAS No	Title	Target number of patients agreed?	Target range minimum	Target range maximum	Target date to recruit patients agreed?	Planned Recruitment end date	Total no of patients recruited at the agreed target date	Total no of patients recruited (current accrual)	Date study actually closed to recruitment at STH	Reason for closure of recruitment at STH
1	11/YH/0009	64911	MiroCam endoscopy of the small bowel in patients with GI bleeding/iron deficiency Anaemia and findings at upper and lower GI endoscopy of unclear bleeding potential	Number Agreed	20	20	Date Agreed	01/01/2017	2	2	18/10/2016	Recruitment Finished
2	GTAC177	75114	A Phase I study of the safety, tolerability and biological effect of single and repeat administration of the selectively replication-competent herpes virus HSV1716 into the tumour-bearing pleural cavity (intrapleural) in patients with inoperable malignant pleural mesothelioma	Range Agreed	12	18	Date Agreed	26/09/2016	10	10	26/09/2016	Recruitment Finished
3	12/LO/1731	116030	International non-randomized, single arm, long-term follow-up study of patients with uncontrolled hypertension	Range Agreed	12	17	Date Agreed	31/01/2015	12	13	09/09/2016	Recruitment Finished
4	13/NW/0002	114402	Prospective, randomised, controlled investigation comparing the safety and performance of 032-11 Surgical Haemostat 2g Applicator with FLOSEAL® Hemostatic Matrix as an adjunctive haemostat in cardiac surgery and thoracic aortic surgery.	Number Agreed	17	17	Not Available / Not Agreed			9	16/11/2016	Recruitment Finished

5	13/LO/1557	135995	CALM-NET: A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving Deep Subcutaneous Administrations of Somatuline® (lanreotide) Autogel® to treat the Symptoms of Functioning Midgut NeuroEndocrine Tumours (NET).	Number Agreed	4	4	Date Agreed	22/07/2016	6	6	21/07/2016	Recruitment Finished
6	14/NW/1294	158613	A Phase III, multi-center, double-blind, placebo controlled, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing's disease who are candidates for medical therapy.	Number Agreed	2	2	Date Agreed	17/04/2017	1	1	10/02/2017	Recruitment Finished
7	13/LO/1328	137191	A multicentre, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction	Number Agreed	6	6	Date Agreed	31/12/2016	5	5	09/12/2016	Recruitment Finished
8	15/NE/0086	177616	A phase iii, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of Lampalizumab administered intravitreally to patients with Geographic atrophy secondary to Age-related macular degeneration	Number Agreed	4	4	Date Agreed	30/09/2016	1	1	30/09/2016	Recruitment Finished

9	15/YH/0003	167451	ZINN - Randomized, Doubleblind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban Therapy for Women in Spontaneous Preterm Labor	Range Agreed	3	12	Date Agreed	16/06/2017	1	1	21/04/2017	Withdrawn By Sponsor
10	15/LO/0448	171812	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)	Range Agreed	5	6	Date Agreed	31/12/2016	2	2	01/11/2016	Recruitment Finished
11	15/LO/0337	171675	A randomized, double-blind, placebo-controlled, prospective, multicenter, parallel group study to assess the safety and efficacy of macitentan in patients with portopulmonary hypertension	Range Agreed	2	3	Date Agreed	31/03/2017	0	0	31/03/2017	Recruitment Finished
12	14/SS/1087	164169	A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC4061, 30mg to 120mg/day, split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease	Number Agreed	1	1	Date Agreed	31/05/2017	1	1	28/02/2017	Recruitment Finished
13	15/LO/0413	171579	Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration.	Range Agreed	2	10	Date Agreed	09/09/2016	2	2	09/09/2016	Recruitment Finished

14	15/YH/0127	174190	An open label extension study to investigate the long term safety, tolerability and efficacy of PF-02545920 in subjects with Huntington's disease who previously completed study A8241021	Number Agreed	1	1	Date Agreed	01/10/2017	3	3	06/04/2017	Withdrawn By Sponsor
15	15/LO/0443	172123	OPTIMISSM: Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma.	Number Agreed	10	10	Date Agreed	28/02/2017	2	2	29/03/2017	Recruitment Finished
16	15/YH/0287	174975	An open-label study of Dupilumab in patients with atopic dermatitis who participated in previous Dupilumab clinical trials.	Number Agreed	5	5	Date Agreed	28/02/2017	10	10	28/02/2017	Recruitment Finished
17	15/SC/0409	183061	Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration.	Range Agreed	5	10	Date Agreed	30/11/2017	2	2	07/04/2017	Recruitment Finished
18	15/WM/0207	178335	A Randomized, Open-label, Phase 3 Study Assessing Safety and Efficacy in Subjects with Relapsed and Refractory Multiple Myeloma Receiving Once-weekly Carfilzomib Compared to Twice-weekly Carfilzomib in Combination with Dexamethasone.	Range Agreed	4	5	Date Agreed	30/08/2016	5	5	05/08/2016	Recruitment Finished
19	15/LO/0684	177109	Effects of ODM-109 on respiratory function in patients with ALS. A randomised, double blind, placebo-controlled, cross-over, 3 period, multicentre study with open-label follow-up extension.	Range Agreed	5	10	Date Agreed	31/07/2016	5	5	31/07/2016	Recruitment Finished

20	15/LO/1074	182401	“ExplorerTM3” A multi-centre, randomised, placebo controlled, double blinded, multiple dose trial investigating safety, pharmacokinetics and pharmacodynamics of concizumab administered subcutaneously to haemophilia A subjects. Trial ID: NN7415-4159	Number Agreed	1	1	Date Agreed	31/03/2017	0	0	05/10/2016	Recruitment Finished
21	15/LO/1670	188788	Randomised, placebo-controlled, double-blind Phase 2 study of Patritumab (U3-1287) in combination with Cetuximab plus platinum-based therapy in first line setting in subjects with recurrent or metastatic squamous cell carcinoma of the head and neck.	Range Agreed	0	12	Date Agreed	21/07/2017	3	3	21/06/2017	Recruitment Finished
22	15/YH/0538	190662	Phase 3 Study Investigating the Efficacy, Safety and Tolerability of Dupilumab Monotherapy Administered to Adult Patients With Atopic Dermatitis (AD) Who Are Not Adequately Controlled With or Are Intolerant to Oral Cyclosporine or When This Treatment is Not Medically Advisable.	Number Agreed	5	5	Date Agreed	31/10/2016	7	7	03/10/2016	Recruitment Finished
23	15/EM/0443	187983	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	Number Agreed	7	7	Date Agreed	30/03/2017	7	7	30/03/2017	Recruitment Finished
24	16/EM/0119	201823	The BAHA Attract System with Cochlear BAHA 5 SuperPower.	Range Agreed	3	5	Date Agreed	30/07/2016	4	7	28/09/2016	Recruitment Finished
25	16/LO/0448	198164	A Phase 2 study of LY2606368 in patients with extensive stage disease small cell lung cancer.	Number Agreed	1	1	Date Agreed	31/08/2017	0	0	17/01/2017	Recruitment Finished

26	15/NW/0553	183360	A Prospective Observational Trial to Evaluate the Correlation of T-SPOT® Response to CMV Infection and T cell-mediated Acute Graft Rejection. The PROTECT Study.	Number Agreed	10	10	Date Agreed	31/01/2017	2	2	12/09/2016	Recruitment Finished
27	16/LO/0586	200579	An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment.	Number Agreed	3	3	Date Agreed	31/07/2017	10	10	24/02/2017	Recruitment Finished
28	15/LO/1612	186328	A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Cancer.	Number Agreed	2	2	Date Agreed	31/12/2016	8	8	27/12/2016	Recruitment Finished
29	16/WM/0197	202991	A multi-center, randomized, double-blind, placebo controlled, parallel group phase 2a study to assess the efficacy of RO5459072 in patients with primary Sjogren's syndrome.	Number Agreed	3	3	Date Agreed	31/08/2017	0	0	06/03/2017	Recruitment Finished
30	15/LO/0834	172183	IMPassion 130 - A Phase III, multicentre, randomised, placebo-controlled study of MPDL3280A (Anti-PD-L1 antibody) in combination with nab-Paclitaxel compared with placebo with nab-Paclitaxel for patients with previously untreated metastatic triple-negative breast cancer.	Range Agreed	2	4	Date Agreed	31/07/2017	3	3	08/05/2017	Recruitment Finished

31	16/SC/0351	205155	A Phase III, open-label, multicenter, three-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy vs. regorafenib in patients with previously treated unresectable locally advanced or metastatic colorectal adenocarcinoma.	Number Agreed	2	2	Date Agreed	30/04/2017	2	2	09/12/2016	Recruitment Finished